REMITLY GLOBAL INC (RELY)

US75960P1049 - Common Stock

21.04  +0.36 (+1.74%)

After market: 21.04 0 (0%)

Fundamental Rating

4

Overall RELY gets a fundamental rating of 4 out of 10. We evaluated RELY against 100 industry peers in the Financial Services industry. While RELY has a great health rating, there are worries on its profitability. RELY is valued quite expensively, but it does show have an excellent growth rating.



1

1. Profitability

1.1 Basic Checks

In the past year RELY has reported negative net income.
RELY had a positive operating cash flow in the past year.
In the past 5 years RELY always reported negative net income.
RELY had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -6.83%, RELY is doing worse than 90.00% of the companies in the same industry.
Looking at the Return On Equity, with a value of -10.51%, RELY is doing worse than 82.00% of the companies in the same industry.
Industry RankSector Rank
ROA -6.83%
ROE -10.51%
ROIC N/A
ROA(3y)-11.32%
ROA(5y)-13.36%
ROE(3y)-18.03%
ROE(5y)-25.45%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

RELY has a Gross Margin of 65.81%. This is in the better half of the industry: RELY outperforms 77.00% of its industry peers.
RELY's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for RELY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.55%
GM growth 5YN/A

8

2. Health

2.1 Basic Checks

RELY does not have a ROIC to compare to the WACC, probably because it is not profitable.
RELY has more shares outstanding than it did 1 year ago.
RELY has a worse debt/assets ratio than last year.

2.2 Solvency

RELY has an Altman-Z score of 8.13. This indicates that RELY is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 8.13, RELY belongs to the best of the industry, outperforming 92.00% of the companies in the same industry.
The Debt to FCF ratio of RELY is 0.03, which is an excellent value as it means it would take RELY, only 0.03 years of fcf income to pay off all of its debts.
RELY's Debt to FCF ratio of 0.03 is amongst the best of the industry. RELY outperforms 91.00% of its industry peers.
RELY has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
RELY's Debt to Equity ratio of 0.00 is amongst the best of the industry. RELY outperforms 89.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.03
Altman-Z 8.13
ROIC/WACCN/A
WACC8.96%

2.3 Liquidity

A Current Ratio of 2.66 indicates that RELY has no problem at all paying its short term obligations.
RELY's Current ratio of 2.66 is amongst the best of the industry. RELY outperforms 81.00% of its industry peers.
RELY has a Quick Ratio of 2.66. This indicates that RELY is financially healthy and has no problem in meeting its short term obligations.
RELY has a Quick ratio of 2.66. This is amongst the best in the industry. RELY outperforms 82.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 2.66

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 39.66% over the past year.
RELY shows a strong growth in Revenue. In the last year, the Revenue has grown by 35.19%.
Measured over the past years, RELY shows a very strong growth in Revenue. The Revenue has been growing by 54.31% on average per year.
EPS 1Y (TTM)39.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%105%
Revenue 1Y (TTM)35.19%
Revenue growth 3Y54.31%
Revenue growth 5YN/A
Sales Q2Q%39.27%

3.2 Future

RELY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 46.17% yearly.
The Revenue is expected to grow by 22.61% on average over the next years. This is a very strong growth
EPS Next Y60.44%
EPS Next 2Y39.31%
EPS Next 3Y32.82%
EPS Next 5Y46.17%
Revenue Next Year33.41%
Revenue Next 2Y28.69%
Revenue Next 3Y25.69%
Revenue Next 5Y22.61%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RELY. In the last year negative earnings were reported.
Also next year RELY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

RELY's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 46.66
EV/EBITDA N/A

4.3 Compensation for Growth

RELY's earnings are expected to grow with 32.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.31%
EPS Next 3Y32.82%

0

5. Dividend

5.1 Amount

No dividends for RELY!.
Industry RankSector Rank
Dividend Yield N/A

REMITLY GLOBAL INC

NASDAQ:RELY (11/22/2024, 5:34:22 PM)

After market: 21.04 0 (0%)

21.04

+0.36 (+1.74%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryFinancial Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.17B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.83%
ROE -10.51%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 65.81%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.66
Quick Ratio 2.66
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)39.66%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y60.44%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)35.19%
Revenue growth 3Y54.31%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y